文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

靶向降钙素原保护血管屏障完整性

Targeting Procalcitonin Protects Vascular Barrier Integrity.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01
一句话结论降钙素原通过DPP4激活破坏VE-钙黏蛋白致内皮高通透性,靶向其受体或DPP4(如西格列汀)可减少毛细血管渗漏。

该研究纳入50例心脏手术患者进行前瞻性观察,发现术后降钙素原升高者液体需求增加2倍(P<0.01)、血管升压药需求增加1.8倍(P<0.05)、微循环受损(灌注血管降至63.5±2.8%,P<0.05)。体外和小鼠实验显示降钙素原经DPP4激活诱导内皮和肺毛细血管通透性分别增加1.4倍和2.3倍(均P<0.001),靶向降钙素原受体或DPP4可使脓毒症所致毛细血管渗漏分别减少54±10.1%和60.4±6.9%(均P<0.01)。心脏手术前使用西格列汀与微循环改善(灌注血管74.1±1.7% vs 未用药者68.6±1.9%,P<0.05)及术后液体需求减少2.3倍(P<0.05)、升压药需求减少1.8倍(P<0.05)相关。作者认为靶向降钙素原对内皮的作用是全身炎症伴高降钙素原血症时保护血管完整性的可行手段。

要点

  • 心脏手术后降钙素原升高者液体需求增加2倍(P<0.01)、升压药需求增加1.8倍(P<0.05)、灌注血管降至63.5±2.8%(P<0.05)。
  • 降钙素原经DPP4激活诱导内皮通透性增加1.4倍、肺毛细血管通透性增加2.3倍(均P<0.001),机制为破坏VE-钙黏蛋白。
  • 脓毒症高降钙素原血症时靶向降钙素原受体或DPP4使毛细血管渗漏分别减少54±10.1%和60.4±6.9%(均P<0.01)。
  • 心脏手术前使用西格列汀者术后灌注血管74.1±1.7% vs 未用药者68.6±1.9%(P<0.05),液体需求减少2.3倍、升压药需求减少1.8倍(均P<0.05)。
  • 作者认为靶向降钙素原对内皮的作用是全身炎症伴高降钙素原血症时保护血管完整性的可行手段。

适用人群与场景

  • 接受心脏手术的50例患者(前瞻性观察性临床研究)。
  • 小鼠多微生物脓毒症模型(用于评估DPP4抑制)。
  • 慢性服用DPP4抑制剂西格列汀的心脏手术患者(临床验证)。

处置流程与药物剂量

  • 心脏手术前使用西格列汀(慢性用药者)与术后微循环改善、液体和升压药需求降低相关,非研究推荐方案。

研究设计与关键结果

  • 前瞻性观察性临床研究纳入50例心脏手术患者,术后降钙素原升高者液体需求增加2倍(P<0.01)、血管升压药需求增加1.8倍(P<0.05)、灌注血管降至63.5±2.8%(P<0.05)。
  • 体外实验显示降钙素原诱导内皮通透性增加1.4倍、肺毛细血管通透性增加2.3倍(均P<0.001),通过破坏VE-钙黏蛋白实现。
  • 降钙素原效应依赖DPP4激活;小鼠脓毒症高降钙素原血症时靶向降钙素原受体或DPP4使毛细血管渗漏分别减少54±10.1%和60.4±6.9%(均P<0.01)。
  • 心脏手术前使用西格列汀者术后灌注血管74.1±1.7% vs 未用药者68.6±1.9%(P<0.05),液体需求减少2.3倍(P<0.05)、升压药需求减少1.8倍(P<0.05)。

证据类型、等级与局限

  • 证据类型:前瞻性观察性临床研究、体外实验、小鼠模型。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为靶向降钙素原对内皮的作用是全身炎症伴高降钙素原血症时保护血管完整性的可行手段。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Capillary leakage frequently occurs during sepsis and after major surgery and is associated with microvascular dysfunction and adverse outcome. Procalcitonin is a well-established biomarker in inflammation without known impact on vascular integrity. Objectives: We determined how procalcitonin induces endothelial hyperpermeability and how targeting procalcitonin protects vascular barrier integrity. Methods: In a prospective observational clinical study, procalcitonin levels were assessed in 50 patients who underwent cardiac surgery and correlated to postoperative fluid and vasopressor requirements along with sublingual microvascular functionality. Effects of the procalcitonin signaling pathway on endothelial barrier and adherens junctional integrity were characterized in vitro and verified in mice. Inhibition of procalcitonin activation by dipeptidyl-peptidase 4 (DPP4) was evaluated in murine polymicrobial sepsis and clinically verified in cardiac surgery patients chronically taking the DPP4 inhibitor sitagliptin. Measurements and Main Results: Elevated postoperative procalcitonin levels identified patients with 2-fold increased fluid requirements (P < 0.01), 1.8-fold higher vasopressor demand (P < 0.05), and compromised microcirculation (reduction to 63.5 ± 2.8% of perfused vessels, P < 0.05). Procalcitonin induced 1.4-fold endothelial and 2.3-fold pulmonary capillary permeability (both Ps < 0.001) by destabilizing VE-cadherin. Procalcitonin effects were dependent on activation by DPP4, and targeting the procalcitonin receptor or DPP4 during sepsis-induced hyperprocalcitonemia reduced capillary leakage by 54 ± 10.1% and 60.4 ± 6.9% (both Ps < 0.01), respectively. Sitagliptin before cardiac surgery was associated with augmented microcirculation (74.1 ± 1.7% vs. 68.6 ± 1.9% perfused vessels in non-sitagliptin-medicated patients, P < 0.05) and with 2.3-fold decreased fluid (P < 0.05) and 1.8-fold reduced vasopressor demand postoperatively (P < 0.05). Conclusions: Targeting procalcitonin's action on the endothelium is a feasible means to preserve vascular integrity during systemic inflammation associated with hyperprocalcitonemia.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Brabenec L, Müller M, Hellenthal KEM, et al. Targeting Procalcitonin Protects Vascular Barrier Integrity. Am J Respir Crit Care Med. 2022. PMID: 35699655. doi:10.1164/rccm.202201-0054OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。